Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 7 Days
CMS’s GENEROUS Model moved from concept to nationwide Medicaid implementation signal, with all states applying to participate in a most-favored-nation drug pricing framework—creating a potentially major shift in Medicaid pharmacy spend, state budget predictability, and payer/manufacturer contracting dynamics (AHA). At the same time, scrutiny is intensifying over carve-outs and parallel Medicare drug pilots—particularly obesity drug coverage and “Bridge” pricing—
Related Articles
How TrumpRx Brand-Name Drug Prices Compare to Other Countries
TrumpRx prices for brand-name drugs are about as likely to be higher as lower compared to average prices in other wealthy countries, according to an analysis that compares 32 brand-name drugs (without...
Analysis: Prices for Many Brand-Name TrumpRx Drugs Are Cheaper than the Average Price in Other Wealthy Countries, But Are Almost as Likely To Be More Expensive
Consumers who buy brand-name prescription drugs without an available generic or biosimilar at the prices available through the new TrumpRx website are about as likely to pay more as pay less for those...
Florida AG sues PBMs, pharmas over rise in insulin prices
Florida AG sues PBMs, pharmas over rise in insulin prices Fierce Healthcare
The Role of Comparator Selection in Ex-US HTA and International Drug Pricing
Pfizer, Lilly 'most favored nation' deals to give US share of raised foreign prices
The "most favored nation" drug pricing deals that Pfizer and Eli Lilly signed with the Trump administration suggest the companies will give the government a share of increased revenue they generate fr...
Hospitals are scrambling to keep 340B discounts. Here’s what to know
Hospitals are scrambling to keep 340B discounts. Here’s what to know Modern Healthcare News
FAQ: How the GENEROUS Model Applies MFN Pricing to Medicaid
Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes
Millions of Americans could lose access to cheap Canadian prescriptions next month: 3 notes Becker's Hospital Review
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
340B hospitals lag behind peers in charity care spending: report
The findings add new fodder for critics who say 340B has ballooned out of control with no corresponding benefit to patients. One hospital group called the report “another in a long line of misleading ...